Latestage trials on way for German vaccine
2020-12-16 00:00
German biotechnology company CureVac has begun enrolling participants into latestage trials for a COVID candidate vaccine that remains stable at standard refrigeration temperature for three months.The vaccine, which is called CVnCoV, uses similar messenger RNA technology to the treatments from Pfizer and Moderna, without posing the logistical challenge of ultracold storage temperatures.The CureVac vaccine elicited a robust immune response in early trials, and newly announced Phase b studies will test efficacy across , participants in Europe and Latin America.                                                                                                                                                                                                                                                                           !CDATA            function shareweixin              var ua  navigator.userAgent.toLowerCase              ifiphoneipadipod.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyiosschemeencodeIos                            else ifandroid.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyandroidschemeencodeAndroid                            else                window.openwww.chinadaily.com.cnmobiledaily.html